The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

Drug Design Development and Therapy is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of drug discovery, pharmaceutical science, and pharmacology. With an impressive Q1 ranking in its categories as of 2023, this journal is recognized for its significant contributions to the understanding of drug design and therapeutic innovations, making it an invaluable resource for researchers, professionals, and students alike. Established in 2007 and committed to open-access since 2008, the journal provides an inclusive platform for disseminating high-quality research from around the globe. With a robust impact factor and remarkable Scopus rankings, including a 24th place in Pharmaceutical Science and a 48th place in Pharmacology, it reflects a strong percentile performance, ensuring that published articles reach and impact a wide audience. By fostering the exchange of cutting-edge information on drug development and delivery systems, Drug Design Development and Therapy continues to play a crucial role in the ongoing battle against disease, promoting innovative approaches to therapeutic solutions and enhancing patient care.

Advances in Pharmacology and Pharmacy is a pioneering journal devoted to the dissemination of cutting-edge research in the fields of pharmacology and pharmaceutical sciences. Published by Horizon Research Publishing, this peer-reviewed journal boasts a commitment to advancing knowledge and innovation, making it an essential resource for researchers, industry professionals, and students alike. With an ISSN of 2332-0036 and an E-ISSN of 2332-0044, it provides a platform for high-quality research articles that explore new therapeutic approaches, drug development strategies, and the regulatory aspects of pharmaceutical science. Although currently lacking a formal impact factor, the journal's emphasis on open access ensures that articles are widely available, promoting the sharing of valuable insights and collaborative efforts in the scientific community. Located at 506 N Garfield Ave, Ste 210, Alhambra, CA 91801, the journal welcomes contributions from diverse areas within pharmacology and pharmacy, reinforcing its significance as a vital resource in the ever-evolving landscape of pharmaceutical research.

Indian Journal of Pharmaceutical Education and Research, published by the Association of Pharmaceutical Teachers of India, is a pivotal platform for scholarly discussion in the field of pharmacology, toxicology, and pharmaceutics. ISSN 0019-5464, this esteemed journal aims to foster the exchange of innovative research, clinical advancements, and educational practices within the pharmaceutical sciences community. As a Q3-ranked journal in its category as of 2023, it reflects a commitment to upholding the standards of academic excellence and contributes significantly to the ongoing development of pharmaceutical education. The journal is a valuable resource for researchers, professionals, and students, with content spanning various key areas including drug formulation, safety, and the latest trends in pharmaceutical education. By providing open access to its research and reviews, the journal ensures that vital information is disseminated widely, promoting collaboration and learning among stakeholders in the pharmaceutical sector. Based in Bangalore, India, the journal has been instrumental in highlighting regional research while fostering a global dialogue in pharmaceutical sciences. As it continues its journey from 2008 to 2024, it remains dedicated to impacting the field through rigorous peer-reviewed content and engaging with contemporary challenges in healthcare and education.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.

SAUDI PHARMACEUTICAL JOURNAL, published by Elsevier, stands as a pivotal platform for scholarly communication within the realm of pharmaceutical sciences and pharmacology. With a commendable Q2 ranking in both Pharmaceutical Science and Pharmacology for 2023, this journal reflects a strong commitment to advancing scientific understanding and innovation. Open Access since 2009, the journal ensures that cutting-edge research is readily accessible to researchers, professionals, and students around the globe, fostering collaboration and knowledge sharing. Based in the Netherlands, the journal covers a wide scope of topics, contributing to a cumulative understanding of drug development, therapeutic strategies, and pharmaceutical education. With a significant presence in Scopus rankings—#57 in Pharmaceutical Science and #116 in Pharmacology—SAUDI PHARMACEUTICAL JOURNAL is a trusted resource for high-quality research that shapes the future of pharmaceutical sciences.

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

PHARMACEUTICAL BIOLOGY, published by Taylor & Francis Ltd, is a prominent open-access journal that has been a cornerstone of research in the life sciences since its convergence in 1961. With a strong focus on Complementary and Alternative Medicine, Pharmaceutical Science, and Drug Discovery, this journal is dedicated to disseminating groundbreaking research that intersects pharmaceuticals and biology. Acknowledged for its rigorous peer-review process, it holds a prestigious Q1 ranking in Pharmaceutical Science and exemplifies the commitment to quality and impact in the field, boasting an impressive Scopus rank of #14/105 in the complementary and alternative medicine category. Researchers keen on advancing their knowledge in these fields will find PHARMACEUTICAL BIOLOGY an invaluable resource, offering accessibility since its shift to open access in 2017. This journal presents a platform for innovative studies that contribute to the evolving understanding of pharmaceutical applications and biological interactions, serving as an essential hub for researchers, professionals, and students alike.